Brief: Biocartis Launch Of Rapid CE-marked IVD Idylla GeneFusion Panel For Fast Treatment Decisions In Lung Cancer
20/06/2022 06:04
June 20 (Reuters) - Biocartis Group NV BCART.BR :
* BIOCARTIS ANNOUNCES LAUNCH OF ITS RAPID CE-MARKED IVD
IDYLLA
GENEFUSION PANEL FOR FAST TREATMENT DECISIONS IN LUNG CANCER
* IDYLLA GENEFUSION PANEL AVAILABLE AS RAPID CE-MARKED IVD
LUNG
CANCER TESTING SOLUTION FOR LABORATORIES, WITH RESULTS WITHIN
180 MINUTES
Source text for Eikon: ID:nGNE7T0tpt
Further company coverage: BCART.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Biocartis NV
See all newsBrief: Biocartis Group NV Appoints Randy Polonsky As Chief Financial Officer
Brief: Biocartis Appoints New Chief Business Officer, VP Global Marketing
Brief: Biocartis And Merck To Collaborate
Brief: Biocartis's Secured Creditors Enforced Their Security Over Subsidiaries Shares
Brief: Biocartis Announces Expansion Of Its Collaboration With Apis Assay Technologies